- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01908530
Clinical Assessment of a Novel Microprobe Array Continuous Glucose Monitor for Type 1 Diabetes
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Continuous knowledge of ambient glucose levels will be of benefit to patients with T1DM, especially those with troublesome hypoglycaemia. Existing monitors require skin puncture to access interstitial fluid and sense its glucose content. Despite their clinical benefits, their use is associated with discomfort and their accuracy is questionable in hypoglycaemia. The development of a painless continuous glucose monitor is regarded as the top research priority by patients with diabetes. A novel continuous glucose monitoring device has been developed at Imperial College based on microprobe technology. It consists of a small, wearable patch (~1 cm2), the size of a conventional postage stamp, containing microscopic projections (microprobes) that penetrate only the outermost skin layer. It accesses interstitial fluid to sense its glucose content without stimulating skin nerve fibres or reaching blood vessels within skin layers. The microprobe surface has the consistency of sandpaper. It is pushed into the skin with an applicator allowing it to penetrate through the skin layers and access the interstitial fluid in a minimally invasive manner. The device is disposable and optimum performance will be assessed over five days. The advantages of microprobe technology have been demonstrated in other clinical situations and include painless insertion, absence of bleeding and a low infection risk. The large surface area utilised in our microprobe device has the potential to improve device sensitivity and accuracy. Pre-clinical validation tests have demonstrated the ability of the device to respond accurately to variable glucose concentrations and to penetrate the outermost skin layer without fracture. We aim now to further develop the device through clinical studies in non-diabetic subjects and subjects with type 1 diabetes to allow painless accurate continuous glucose monitoring.
The study will recruit 16 non-diabetic subjects and 20 subjects with type 1 diabetes.
It will be conducted over four phases;
oPhase 1 will assess safety, as a primary outcome, and efficacy, as a secondary outcome, in non-diabetic subjects over six hours in the clinical research facility where the device will be fitted and a cannula inserted for venous sampling every 15 minutes to measure venous blood glucose (YSI). Safety will be assessed with regards to skin inflammation and pain. Efficacy will be assessed in this phase by assessing magnitude of current measured by the microprobe array sensor and comparison of measured ISF glucose concentrations to simultaneous venous blood glucose samples (YSI).
oPhase 2 will also assess safety, as a primary outcome, and efficacy, as a secondary outcome, in non-diabetic subjects over a period of 24 hours. The first six hours in the clinical research facility (same as phase 1), then subject will be allowed to go home with the device to assess safety over that period.
oPhase 3 aims to assess efficacy of the device as a primary outcome and safety as a secondary outcome. This will be in subjects with type 1 diabetes over 24 hours as inpatients. Efficacy will be assessed mechanically (by the ability to penetrate the stratum corneum) and functionally (by the ability to accurately sense ISF glucose). The derived ISF glucose levels will be compared with simultaneous venous glucose samples (YSI) and with a commercially available CGM device (iPro2, Medtronic). Assessment of microprobe penetration of the stratum corneum will be performed using confocal microscopy, optical coherence tomography and in skin biopsies.
oPhase 4 aims to assess efficacy of the device as a primary outcome and safety as a secondary outcome. This will be in subjects with type 1 diabetes over 5 days in ambulatory situation. Efficacy will be assessed by comparing microprobe sensor derived ISF glucose levels against ISF glucose levels measured using a commercially available CGM device (iPro2, Medtronic).
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
London, United Kingdom, W2 1PG
- Imperial College London
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
For phases 1 and 2:
Inclusion Criteria:
• Adults over 18 years of age
Exclusion Criteria:
- History of upper limb neuropathy or radiculopathy
- History of pre-existing skin condition
- Pregnant or planning pregnancy in next 12 months
- Breastfeeding
- Enrolled in other clinical trials
- uncontrolled concurrent illness
- Have active malignancy or under investigation for malignancy
For phases 3 and 4:
Inclusion Criteria:
- Adults over 18 years of age.
- Diagnosed with Type 1 diabetes for greater than 1 year.
- HbA1c less than or equal to 9.0 % (75 mmol/mol).
- Registered with a General Practitioner.
Exclusion criteria:
- History of diabetic dermopathy or pre-existing skin condition
- History of upper limb neuropathy or radiculopathy
- Pregnant or planning pregnancy in next 12 months
- Breastfeeding
- Enrolled in other clinical trials
- uncontrolled concurrent illness
- physical or visual impairment preventing sensor's use
- Have active malignancy or under investigation for malignancy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Microprobe Glucose Sensor Phase 1
The microprobe array continuous glucose sensor will be applied to healthy volunteers for 6 hours
|
Assessment of safety and accuracy of a novel continuous glucose monitor based on microprobe technology.
Other Names:
|
Experimental: Microprobe Glucose Sensor Phase 2
The microprobe array continuous glucose sensor will be applied to healthy volunteers for 24 hours
|
Assessment of safety and accuracy of a novel continuous glucose monitor based on microprobe technology.
Other Names:
|
Experimental: Microprobe Glucose Sensor Phase 3 and 4
The microprobe array continuous glucose sensor will be applied to participants with type 1 diabetes
|
Assessment of safety and accuracy of a novel continuous glucose monitor based on microprobe technology.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participant Developed the Skin Inflammation
Time Frame: 24 hours
|
The study aims to assess safety of the use of microprobe array continuous glucose sensor with regards to skin inflammation.
|
24 hours
|
Difference to the Venous Blood Glucose MARD
Time Frame: 24 hours
|
Phase 3 of the study aim to assess efficacy of the device in people with type 1 diabetes.
This will be done in comparison to venous blood glucose using YSI machine in a controlled environment over 24 hours (phase 3). it was originally planned to then compare this to ISF glucose in ambulatory situation over five days (phase 4) however phase 4 did not go ahead.
Measured using mean absolute relative difference with respect to venous blood glucose
|
24 hours
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pain Score
Time Frame: 24 hours
|
The study aims to assess safety of the device with regards to pain degree in comparison to venflon insertion and insertion of an existing continuous glucose monitor (Medtronic iPro2 CGM system, Northridge, California).
This will be done at each phase of the four study phases.
|
24 hours
|
Number of Participant Developed Skin Penetration
Time Frame: 24 hours
|
This done using Optical Coherence Tomography and Confocal Microscopy.
Measure = variation in penetration depth of microprobe needles over 24 hours
|
24 hours
|
Detectable Signal
Time Frame: 24 hours
|
This is a secondary outcome for phases 1 & 2.
|
24 hours
|
Correlation With Venous Blood Glucose
Time Frame: 24 hours
|
This is a secondary outcome for phases 1 and 2. It is a primary outcome for phase 3. Using MARD.
|
24 hours
|
Acceptability Questionnaire
Time Frame: 24 hours
|
This is a secondary outcome for phases 3 and 4.
|
24 hours
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Desmond Johnston, PhD, FRCP, Professor of Diabetes & Endocrinology - Imperial College London
Publications and helpful links
General Publications
- Pickup JC, Freeman SC, Sutton AJ. Glycaemic control in type 1 diabetes during real time continuous glucose monitoring compared with self monitoring of blood glucose: meta-analysis of randomised controlled trials using individual patient data. BMJ. 2011 Jul 7;343:d3805. doi: 10.1136/bmj.d3805.
- Battelino T, Phillip M, Bratina N, Nimri R, Oskarsson P, Bolinder J. Effect of continuous glucose monitoring on hypoglycemia in type 1 diabetes. Diabetes Care. 2011 Apr;34(4):795-800. doi: 10.2337/dc10-1989. Epub 2011 Feb 19.
- El-Laboudi A, Oliver NS, Cass A, Johnston D. Use of microneedle array devices for continuous glucose monitoring: a review. Diabetes Technol Ther. 2013 Jan;15(1):101-15. doi: 10.1089/dia.2012.0188. Epub 2012 Dec 12.
- Khanna P, Strom JA, Malone JI, Bhansali S. Microneedle-based automated therapy for diabetes mellitus. J Diabetes Sci Technol. 2008 Nov;2(6):1122-9. doi: 10.1177/193229680800200621.
- Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group; Tamborlane WV, Beck RW, Bode BW, Buckingham B, Chase HP, Clemons R, Fiallo-Scharer R, Fox LA, Gilliam LK, Hirsch IB, Huang ES, Kollman C, Kowalski AJ, Laffel L, Lawrence JM, Lee J, Mauras N, O'Grady M, Ruedy KJ, Tansey M, Tsalikian E, Weinzimer S, Wilson DM, Wolpert H, Wysocki T, Xing D. Continuous glucose monitoring and intensive treatment of type 1 diabetes. N Engl J Med. 2008 Oct 2;359(14):1464-76. doi: 10.1056/NEJMoa0805017. Epub 2008 Sep 8.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 13SM0639
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus
-
University of Colorado, DenverMassachusetts General Hospital; Beta Bionics, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Diabetes type1 | Type 1 Diabetes Mellitus | Autoimmune Diabetes | Diabetes Mellitus, Insulin-Dependent | Juvenile-Onset Diabetes | Diabetes, Autoimmune | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | Diabetes Mellitus, Brittle | Diabetes Mellitus, Juvenile-Onset and other conditionsUnited States
-
Guang NingRecruitingType 2 Diabetes Mellitus | Type1 Diabetes Mellitus | Monogenetic Diabetes | Pancreatogenic Diabetes | Drug-Induced Diabetes Mellitus | Other Forms of Diabetes MellitusChina
-
Medical College of WisconsinMedical University of South CarolinaCompletedDiabetes Mellitus | Type 2 Diabetes Mellitus | Adult-Onset Diabetes Mellitus | Non-Insulin-Dependent Diabetes Mellitus | Noninsulin Dependent Diabetes Mellitus, Type IIUnited States
-
Hanmi Pharmaceutical Company LimitedUnknownType2 Diabetes Mellitus | Type1 Diabetes MellitusUnited States
-
Meir Medical CenterCompletedDiabetes Mellitus Type 2 | Diabetes Mellitus, Non-insulin Dependant | Diabetes Mellitus, on Oral Hypoglycemic Treatment | Adult Type Diabetes MellitusIsrael
-
Peking Union Medical College HospitalUnknownType 2 Diabetes Mellitus | Type 1 Diabetes Mellitus | Gestational Diabetes Mellitus | Pancreatogenic Diabetes Mellitus | Pregestational Diabetes Mellitus | Diabetes Patients in Perioperative PeriodChina
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Joslin Diabetes CenterCambridge Medical Technologies, LLCCompletedType 2 Diabetes Mellitus | Type1 Diabetes MellitusUnited States
-
Medical University of South CarolinaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedDiabetes Mellitus, Type 2 | Diabetes Mellitus, Type II | Diabetes Mellitus, Adult-Onset | Diabetes Mellitus, Non-Insulin-Dependent | Diabetes Mellitus, Noninsulin DependentUnited States
-
Medical College of WisconsinMedical University of South Carolina; National Institute of Diabetes and Digestive...Active, not recruitingDiabetes Mellitus, Type 2 | Diabetes Mellitus, Type II | Diabetes Mellitus, Adult-Onset | Diabetes Mellitus, Non-Insulin-Dependent | Diabetes Mellitus, Noninsulin DependentUnited States
Clinical Trials on Microprobe glucose sensor
-
Children's Mercy Hospital Kansas CityWithdrawnType 1 DiabetesUnited States
-
Medtronic DiabetesCompletedDiabetesUnited States
-
University of AlbertaCompleted
-
Corporacion Parc TauliCompletedInflammatory Response to Glucose SensorsSpain
-
Centre Hospitalier Universitaire DijonCompletedDiabetes | Old Age | Institutionalized in EHPAD (French Nursing Home) | Hypoglycemic SyndromeFrance
-
Medtronic DiabetesProfil Institut für Stoffwechselforschung GmbHCompletedDiabetes
-
Icahn School of Medicine at Mount SinaiActive, not recruiting
-
Yale UniversityNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)TerminatedType 1 DiabetesUnited States
-
Centre Hospitalier Sud FrancilienCompleted
-
Portsmouth Hospitals NHS TrustCompletedDiabetes Mellitus | Surgical Procedure, UnspecifiedUnited Kingdom